{"title":"西雅图基因公司和拜耳公司第二次合作开发抗体-药物偶联物","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I7.1962","DOIUrl":null,"url":null,"abstract":"Bayer has formed a second antibody-drug conjugate (ADC) collaboration with Seattle Genetics under which it will obtain worldwide rights to utilise the company’s auristatin-based ADC technology with antibodies to several undisclosed cancer targets. Under the terms of the agreement, which is potentially worth US$520 M, Bayer is responsible for the research, development, manufacturing and commercialisation of all collaboration products. The two companies previously partnered in 2004 to develop an ADC against a single solid tumour target. This collaboration spawned BAY 79-4620, development of which was terminated in 2011.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"131 3 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Seattle Genetics and Bayer Partner for a Second Time to Develop Antibody-Drug Conjugates\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I7.1962\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Bayer has formed a second antibody-drug conjugate (ADC) collaboration with Seattle Genetics under which it will obtain worldwide rights to utilise the company’s auristatin-based ADC technology with antibodies to several undisclosed cancer targets. Under the terms of the agreement, which is potentially worth US$520 M, Bayer is responsible for the research, development, manufacturing and commercialisation of all collaboration products. The two companies previously partnered in 2004 to develop an ADC against a single solid tumour target. This collaboration spawned BAY 79-4620, development of which was terminated in 2011.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"131 3 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-06-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I7.1962\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I7.1962","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Seattle Genetics and Bayer Partner for a Second Time to Develop Antibody-Drug Conjugates
Bayer has formed a second antibody-drug conjugate (ADC) collaboration with Seattle Genetics under which it will obtain worldwide rights to utilise the company’s auristatin-based ADC technology with antibodies to several undisclosed cancer targets. Under the terms of the agreement, which is potentially worth US$520 M, Bayer is responsible for the research, development, manufacturing and commercialisation of all collaboration products. The two companies previously partnered in 2004 to develop an ADC against a single solid tumour target. This collaboration spawned BAY 79-4620, development of which was terminated in 2011.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
